Benzinga | Dec 9, 2021 09:45PM EST

Achilles Therapeutics Presents Positive Data At ESMO I-O Congress 2021 On High-Dose Manufacturing Process For Precision T Cell Therapies Targeting Clonal Neoantigens

-Over 10-fold dose increase at GMP scale with VELOS(tm) Process 2 manufacturing-



-cNeT maintain CD4+ and CD8+ T cell subsets with a highly potent polyclonal phenotype-

-Dosing of patients with high-dose cNeT expected in 1H 2022-